Pharmaceutical Technology-08-02-2014

Customers are looking to reduce risk, increase performance, and optimize productivity.

FDA seeks high quality applications and products to facilitate approvals and reduce safety and supply problems.

Annual study shows CMO technical expertise is not enough.

The latest revisions to the USP General Chapters <41> Balances and <1251> Weighing on an Analytical Balance aim to ensure weighing accuracy and eliminate unnecessary overtesting by simplifying previous descriptions and reflecting current state-of-the-art weighing practices.

Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments.

A techno-economic profiling method supports pharmaceutical process development by helping identify the best manufacturing approach.

The US federal Drug Quality and Security Act (DQSA) and more specifically the Drug Supply Chain Security Act (DSCSA), referring to Title II of the law, requires phase-in of requirements to prevent counterfeiting. An expert discusses how companies should be preparing to meet the requirements of the DSCSA.

Experts from Capsugel and Catalent discuss the rationale of using lipid0basd formulations to improve the oral bioavailability of poorly soluble drugs.

Click the title above to open the Pharmaceutical Technology August 2014 issue in an interactive PDF format.